In this Psychiatric Times 5:36-minute video, Ginger Constantine MD discussed the mechanism of action of PP-01, her company PleoPharma’s investigational dual-mechanism compound currently under evaluation in an active phase 3 clinical trial for cannabis use disorder and cannabis withdrawal.
Search
News Archives
News Signup
FREE: daily or weekly news supporting freedom from dependency
Journal signup
FREE: print journal and emag supporting freedom from dependency
Conference savings
MONEY OFF: for signups
Support our work
To support us giving the recovery field FREE daily news+research, FREE library, FREE journal and subsidised conference training, click the secure Donate link. THANK YOU!
Recent News
